Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most general statements about Cosentyx indications and that pregnancy data are limited are consistent with the provided label excerpts, but several claims are not supported by the provided label text (notably patent/biosimilar availability and specific pregnancy case reports). Overall alignment is partial due to unsupported external-source assertions.
Category Scores
Accurate Statements
Cosentyx is a biologic medication used to treat plaque psoriasis.
Indications and Usage (1.1 Plaque Psoriasis): “COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis…”
Cosentyx is a biologic medication used to treat psoriatic arthritis.
Indications and Usage (1.2 Psoriatic Arthritis): “COSENTYX is indicated for the treatment of active psoriatic arthritis…”
Cosentyx is a biologic medication used to treat ankylosing spondylitis.
Indications and Usage (1.3 Ankylosing Spondylitis): “COSENTYX is indicated for the treatment of active ankylosing spondylitis…”
As of the stated knowledge cutoff, there were no adequate and well-controlled studies in pregnant women to assess fetal risks of Cosentyx.
Use in Specific Populations (8.1 Pregnancy): “Limited human data…” (supports that adequate and well-controlled studies are not established in the provided excerpt).
Unsupported Statements
Human reproductive and developmental studies of Cosentyx have been conducted, but results are limited.
The provided label excerpt under Pregnancy states limited human data and includes an animal embryo-fetal study, but the claim’s wording about reproductive/developmental studies being conducted with results “limited” is not explicitly supported by the supplied label text.
Animal studies of Cosentyx did not provide a clear indication of harm.
The provided Pregnancy excerpt states: “no adverse developmental effects observed…” which is consistent with lack of harm, but the phrase “did not provide a clear indication of harm” is not the label wording and is not explicitly stated as such in the provided excerpt.
A 2017 letter in the New England Journal of Medicine reported a case in which a woman took Cosentyx during the fourth month of pregnancy and gave birth to a normal infant.
No such journal letter/case report details are present in the provided FDA label excerpts.
A 2018 case report noted a woman who took Cosentyx during the third trimester and had an uneventful pregnancy.
No such case report details are present in the provided FDA label excerpts.
A search on DrugPatentWatch.com indicates Cosentyx's patent expires in 2028.
Patent/exclusivity timelines are not addressed in the provided FDA label excerpts.
Patent exclusivity laws may vary globally.
Global patent/exclusivity variation is not addressed in the provided FDA label excerpts.
Patent and exclusivity timelines may affect the availability of generics and biosimilars and potentially increase access to medication for pregnant women.
No patent/exclusivity/access-to-pregnancy claim is supported by the provided FDA label excerpts.
Healthcare providers are advised to monitor pregnancies closely in women who are taking Cosentyx or other biologics in the same drug class (IL-17 inhibitors).
The provided Pregnancy excerpt describes limited human data and animal findings, but does not include a label instruction to “monitor pregnancies closely,” nor does it advise monitoring for other IL-17 inhibitors specifically.
The precise risk to the fetus of Cosentyx remains a subject of ongoing research and clinical observation.
The provided label excerpt says “Limited human data,” but does not explicitly state “ongoing research and clinical observation” regarding precise fetal risk.
Contradictions
Important Omissions
If pregnancy-related statements are made, the label excerpt indicates “limited human data” and provides an animal embryo-fetal study detail (no adverse developmental effects observed in pregnant monkeys up to 30x MRHD). The response did not incorporate this specific label animal-finding context verbatim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported external-source claims (specific pregnancy case reports) and unsupported guidance on pregnancy monitoring and patent-driven access could mislead interpretation of fetal risk or clinical management beyond what is stated in the provided FDA label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided FDA prescribing information excerpts (journal/case report details; patent/exclusivity and access assertions; specific pregnancy monitoring instruction; “ongoing research” phrasing).
Suggested Improvement
Restrict pregnancy safety statements to what the label excerpt explicitly provides (e.g., “limited human data” and the animal embryo-fetal finding) and remove unsupported patent/access and journal case-report specifics unless the exact label language is provided.